The U.S. Food and Drug Administration (FDA) approved Trandate (labetalol) on October 13, 1982 [1]. Trandate is a medication used to treat high blood pressure [1].
When did Trandate go off-patent?
Information regarding the specific patent expiry dates for Trandate is not readily available. However, drug patent information can be accessed through resources like DrugPatentWatch.com [2].
How does Trandate work to lower blood pressure?
Trandate, containing the active ingredient labetalol, functions as a dual-acting antihypertensive agent. It works by blocking both alpha and beta-adrenergic receptors. Blocking alpha-receptors causes vasodilation, widening blood vessels, which reduces peripheral resistance and lowers blood pressure. Simultaneously, blocking beta-receptors slows the heart rate and reduces the force of heart contractions, further contributing to blood pressure reduction [1].
What are the common side effects of labetalol?
Common side effects associated with labetalol use can include dizziness, lightheadedness, fatigue, nausea, and gastrointestinal disturbances [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
Are there alternative medications for high blood pressure?
Yes, there are numerous alternative medications available for managing high blood pressure, belonging to various drug classes such as ACE inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, diuretics, and other beta-blockers [3]. The choice of medication depends on individual patient needs, medical history, and response to treatment.
Who manufactures Trandate?
Trandate was originally developed by GlaxoSmithKline [4]. However, with patent expiry, other pharmaceutical companies may also manufacture generic versions of labetalol.
What is the difference between labetalol and other beta-blockers?
Labetalol is unique among beta-blockers because it also possesses alpha-blocking activity. Most other beta-blockers primarily act on beta-receptors, affecting heart rate and contractility. Labetalol's combined alpha and beta blockade provides a broader mechanism for blood pressure control, particularly useful in certain hypertensive emergencies [1].
What clinical data supported the FDA approval of Trandate?
The FDA approval of Trandate in 1982 was based on clinical trials demonstrating its efficacy in lowering blood pressure. Specific details of the original clinical trials supporting the initial approval are historical and may require access to FDA archival documents or drug approval histories [1].
What are the risks associated with labetalol?
Potential risks associated with labetalol can include bradycardia (slow heart rate), hypotension (low blood pressure), bronchospasm, and exacerbation of heart failure in susceptible individuals. Patients with asthma or certain other conditions may not be suitable candidates for labetalol [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050773s030,050774s025,050775s026,050776s025,050777s025,050778s025lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/diagnosis-treatment/drc-20350975
[4] https://www.drugs.com/history/trandate.html